BioRestorative TherapiesFRA:9OF -3.68%51 Days Payable is 13,094.38 as of Mar. 2026, which is 44% above its 10-year median of 9,125.00. GuruFocus rates FRA:9OF with a GF Score™ of 51/100 and a GF Value™ of €1.26 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 704 Biotechnology companies, BioRestorative Therapies ranks better than 95.6% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9OF vs CVKD, JSPR, APRE: Days Payable Comparison
For the Biotechnology subindustry, BioRestorative Therapies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Days Payable distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioRestorative Therapies's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (FRA:9OF) has a Days Payable of 13,094.38 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioRestorative Therapies and its competitors. This is 44% above median its historical median of 9,125.00. Over the past decade, BioRestorative Therapies' Days Payable has ranged from 4,380.00 to 13,870.00. According to the industry distribution chart, BioRestorative Therapies ranks #31 out of 704 companies in the Biotechnology industry, placing it in the top 4.4%.
Is BioRestorative Therapies' Days Payable too high?
BioRestorative Therapies' current Days Payable of 13,094.38 is 44% above median its 10-year median of 9,125.00. Over the past 10 years, this metric has ranged from a low of 4,380.00 to a high of 13,870.00. The Biotechnology industry median Days Payable is 113.56. BioRestorative Therapies' value of 13,094.38 is 11430.8% above this industry median. Based on the distribution chart, BioRestorative Therapies ranks #31 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Days Payable compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #31 out of 704 companies for Days Payable. This places BioRestorative Therapies in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. BioRestorative Therapies' value of 13,094.38 is 11430.8% above this benchmark. Historically, BioRestorative Therapies' own Days Payable has ranged from 4,380.00 to 13,870.00 over the past decade. While the company's 10-year median is 9,125.00 vs. the industry median of 113.56, BioRestorative Therapies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current Days Payable of 13,094.38 is 11430.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current Days Payable is 13,094.38, which is 44% above median its own 10-year median of 9,125.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.26, compared to a current price of €0.31 — trading 75.1% below its estimated fair value. The current Days Payable is 13,094.38, which is 44% above median its 10-year median of 9,125.00 and 11430.8% above the Biotechnology industry median of 113.56. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current Days Payable is 13,094.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.31 is trading 75.1% below its estimated GF Value™ of €1.26.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
Days Payable: 13,094.38 (44% above median its 10-year median of 9,125.00)
GF Value™: €1.26 vs. price of €0.31 (75.1% below fair value)
Industry Position: 11430.8% above the Biotechnology median (#31 of 704)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score
Get the complete analysis for FRA:9OF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
